[Clinical experiences with the radiation sensitizer MTDQ (Sensorad) in advanced malignancies of the head and neck region and in uterine cancer]. / Klinische Erfahrungen mit dem Radiosensitizer MTDQ (Sensorad) bei fortgeschrittenen Malignomen des Kopf-Hals-Bereiches und bei Gebärmutterkrebs.

33 patients with malignancies of the head and neck and 9 patients with carcinoma uteri received Sensorad combined with megavolt-therapy in a placebo controlled trial. 35% of the Sensorad treated patients with head and neck cancer showed an early radiomucositis. A full regression was achieved in 15 patients and a partial regression in 18 patients thus the drug helped in 79% of the patients treated. No regression was noted in 6 patients and a progression in 3, that means in 21% of patients no benefit was detected. In the placebo control group a benefit was proved for 35% of the patients whereas 65% of the patients showed no benefit. The proportion of benefit to no benefit was 3.66 in the Sensorad group compared to 0.54 in the placebo group. The patients with carcinoma uteri all showed a benefit from the treatment with Sensorad. The number of adverse reactions was small. 4 patients had nausea and gastrointestinal symptoms, 2 allergic reactions and 3 elevated SGOT (21.4%).

Liver lipid peroxidation induced by cholesterol and its treatment with a dihydroquinoline type free radical scavenger in rabbits.

Lipid peroxidation has been induced by means of an atherogenic diet causing hypercholesterolaemia, hypertriglyceridaemia, increased LDL and decreased HDL serum fractions in addition to the fatty degeneration, vacuolization of the liver cells and accumulation of malondialdehyde in the liver. Increased release of acid phosphatase and N-beta-glucuronidase was also observed pointing to cholesterol-induced lysosomal membrane damage. In response to pretreatment with, and simultaneous administration of, 6,6'-methylene bis (2,2-dimethyl-4-methane sulphonic acid sodium salt-1,2-dihydroquinoline) the signs and symptoms of fatty liver degeneration, the tissue, plasma and platelet malondialdehyde concentrations and the LDL serum fraction significantly decreased and HDL serum fraction increased. Lisosomal membrane stability was restored, resulting in physiological acid phosphatase and N-beta-glucuronidase activities. The pathological and clinical aspects of lipid peroxidation in several diseases of the digestive organs and the suggested therapeutic uses of non-toxic radical scavengers have been outlined.

Biochemical markers in carbon-tetrachloride-and galactosamine-induced acute liver injuries: the effects of dihydroquinoline-type antioxidants.

The pharmacological action and possible therapeutic uses of some recently developed synthetic, non-toxic dihydroquinoline-type antioxidants were studied. The effect of the lipid-soluble 6,6-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline) (n = 1, 2 or 3) (MTDQ) on carbon-tetrachloride-induced acute liver injuries was investigated, and that of the water-soluble 6,6-methylene-bis (2,2-dimethyl-4-methansulphonic acid sodium-1,2-dihydroquinoline) (MDS) on galactosamine-induced acute liver injuries in CFLP mice (Lati, Hungary). MTDQ was found suitable for the prevention of acute CCl4-induced liver injuries and MDS for that of acute galactosamine-induced liver injuries. Disappearance or significant diminution of the morphological signs and lesions of lipid degeneration and centro-lobular liver necrosis, decrease of serum GOT activities, and also inflammatory changes induced by galactosamine were observed.